OncoMatch/Clinical Trials/NCT05450744
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
Is NCT05450744 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies 131I-IPA for neoplastic disease.
Treatment: 131I-IPA — This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Prior therapy
Must have received: surgery — glioblastoma
Have had prior surgery for glioblastoma
Cannot have received: systemic therapy
no systemic therapy or radiation therapy for GBM
Cannot have received: radiation therapy
no systemic therapy or radiation therapy for GBM
Cannot have received: any treatment for glioma, excluding surgery
Have had prior treatment for glioma, excluding surgery
Lab requirements
Blood counts
leukocytes ≥3,000/ml; absolute neutrophil count ≥1500/ml; platelets ≥100,000/ml; haemoglobin ≥9g/dl
Kidney function
serum/plasma creatinine ≤1.5×uln or creatinine clearance ≥50 ml/min
Liver function
total bilirubin ≤1.5×uln (≤3×uln for gilbert's syndrome); alt or ast ≤2.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05450744 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages